Literature DB >> 7528766

Mouse complement regulatory protein Crry/p65 uses the specific mechanisms of both human decay-accelerating factor and membrane cofactor protein.

Y U Kim1, T Kinoshita, H Molina, D Hourcade, T Seya, L M Wagner, V M Holers.   

Abstract

Normal host cells are protected from the destructive action of complement by cell surface complement regulatory proteins. In humans, decay-accelerating factor (DAF) and membrane cofactor protein (MCP) play such a biologic role by inhibiting C3 and C5 convertases. DAF and MCP accomplish this task by specific mechanisms designated decay-accelerating activity and factor I cofactor activity, respectively. In other species, including mice, structural and/or functional homologues of these proteins are not yet well characterized. Previous studies have shown that the mouse protein Crry/p65 has certain characteristics of self-protecting complement regulatory proteins. For example, Crry/p65 is expressed on a wide variety of murine cells, and when expressed on human K562 erythroleukemic cells, it prevents deposition of mouse C3 fragments on the cell surface during activation of either the classical or alternative complement pathway. We have now studied factor I cofactor and decay-accelerating activities of Crry/p65. Recombinant Crry/p65 demonstrates cofactor activity for factor I-mediated cleavage of both mouse C3b and C4b. Surprisingly, Crry/p65 also exhibits decay-accelerating activity for the classical pathway C3 convertase strongly and for the alternative pathway C3 convertase weakly. Therefore, mouse Crry/p65 uses the specific mechanisms of both human MCP and DAF. Although Crry/p65, like MCP and DAF, contains tandem short consensus repeats (SCR) characteristic of C3/C4 binding proteins, Crry/p65 is not considered to be a genetic homologue of either MCP or DAF. Thus, Crry/p65 is an example of evolutionary conservation of two specific activities in a single unique protein in one species that are dispersed to individual proteins in another. We propose that the repeating SCR motif in this family has allowed this unusual process of evolution to occur, perhaps driven by the use of MCP and DAF as receptors by human pathogens such as the measles virus.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7528766      PMCID: PMC2191854          DOI: 10.1084/jem.181.1.151

Source DB:  PubMed          Journal:  J Exp Med        ISSN: 0022-1007            Impact factor:   14.307


  49 in total

1.  Genomic organization and polymorphisms of the human C3d/Epstein-Barr virus receptor.

Authors:  A Fujisaku; J B Harley; M B Frank; B A Gruner; B Frazier; V M Holers
Journal:  J Biol Chem       Date:  1989-02-05       Impact factor: 5.157

2.  Complement inhibitor of rat cell membrane resembling mouse Crry/p65.

Authors:  H Takizawa; N Okada; H Okada
Journal:  J Immunol       Date:  1994-03-15       Impact factor: 5.422

Review 3.  Membrane proteins that protect against complement lysis.

Authors:  B P Morgan; S Meri
Journal:  Springer Semin Immunopathol       Date:  1994

4.  Methods for the separation, purification and measurement of nine components of hemolytic complement in guinea-pig serum.

Authors:  R A Nelson; J Jensen; I Gigli; N Tamura
Journal:  Immunochemistry       Date:  1966-03

5.  Third component of human complement: purification from plasma and physicochemical characterization.

Authors:  B D Tack; J W Prahl
Journal:  Biochemistry       Date:  1976-10-05       Impact factor: 3.162

6.  Binding of C3b and C4b by the CR1-like site in murine CR1.

Authors:  K R Kalli; D T Fearon
Journal:  J Immunol       Date:  1994-03-15       Impact factor: 5.422

7.  Analysis of C3b/C3d binding sites and factor I cofactor regions within mouse complement receptors 1 and 2.

Authors:  H Molina; T Kinoshita; C B Webster; V M Holers
Journal:  J Immunol       Date:  1994-07-15       Impact factor: 5.422

8.  Tissue distribution of complement regulatory membrane proteins in rats.

Authors:  K Funabashi; N Okada; S Matsuo; T Yamamoto; B P Morgan; H Okada
Journal:  Immunology       Date:  1994-03       Impact factor: 7.397

9.  Release of decay-accelerating factor (DAF) from the cell membrane by phosphatidylinositol-specific phospholipase C (PIPLC). Selective modification of a complement regulatory protein.

Authors:  M A Davitz; M G Low; V Nussenzweig
Journal:  J Exp Med       Date:  1986-05-01       Impact factor: 14.307

10.  Short consensus repeat-3 domain of recombinant decay-accelerating factor is recognized by Escherichia coli recombinant Dr adhesin in a model of a cell-cell interaction.

Authors:  B Nowicki; A Hart; K E Coyne; D M Lublin; S Nowicki
Journal:  J Exp Med       Date:  1993-12-01       Impact factor: 14.307

View more
  77 in total

1.  Production and functional analysis of rat CD59 and chimeric CD59-Crry as active soluble proteins in Pichia pastoris.

Authors:  R J Quigg; C He; B K Hack; J J Alexander; B P Morgan
Journal:  Immunology       Date:  2000-01       Impact factor: 7.397

Review 2.  How does the macula protect itself from oxidative stress?

Authors:  James T Handa
Journal:  Mol Aspects Med       Date:  2012-04-05

3.  Genetic and therapeutic targeting of properdin in mice prevents complement-mediated tissue injury.

Authors:  Yuko Kimura; Lin Zhou; Takashi Miwa; Wen-Chao Song
Journal:  J Clin Invest       Date:  2010-10       Impact factor: 14.808

Review 4.  The role of complement system in ocular diseases including uveitis and macular degeneration.

Authors:  Purushottam Jha; Puran S Bora; Nalini S Bora
Journal:  Mol Immunol       Date:  2007-09       Impact factor: 4.407

5.  Bacterial expression and membrane targeting of the rat complement regulator Crry: a new model anticomplement therapeutic.

Authors:  Deborah A Fraser; Claire L Harris; Richard A G Smith; B Paul Morgan
Journal:  Protein Sci       Date:  2002-10       Impact factor: 6.725

6.  Decay-accelerating factor induction by tumour necrosis factor-alpha, through a phosphatidylinositol-3 kinase and protein kinase C-dependent pathway, protects murine vascular endothelial cells against complement deposition.

Authors:  Saifur R Ahmad; Elaine A Lidington; Rieko Ohta; Noriko Okada; Michael G Robson; Kevin A Davies; Michael Leitges; Claire L Harris; Dorian O Haskard; Justin C Mason
Journal:  Immunology       Date:  2003-10       Impact factor: 7.397

7.  Increased serum C3 levels in Crry transgenic mice partially abrogates its complement inhibitory effects.

Authors:  H J Kang; L Bao; Y Xu; R J Quigg; P C Giclas; V M Holers
Journal:  Clin Exp Immunol       Date:  2004-05       Impact factor: 4.330

8.  Role of complement activation in obliterative bronchiolitis post-lung transplantation.

Authors:  Hidemi Suzuki; Mark E Lasbury; Lin Fan; Ragini Vittal; Elizabeth A Mickler; Heather L Benson; Rebecca Shilling; Qiang Wu; Daniel J Weber; Sarah R Wagner; Melissa Lasaro; Denise Devore; Yi Wang; George E Sandusky; Kelsey Lipking; Pankita Pandya; John Reynolds; Robert Love; Thomas Wozniak; Hongmei Gu; Krista M Brown; David S Wilkes
Journal:  J Immunol       Date:  2013-09-16       Impact factor: 5.422

Review 9.  Complement regulation during pregnancy.

Authors:  Hector Molina
Journal:  Immunol Res       Date:  2005       Impact factor: 2.829

10.  Tubulointerstitial injury induced in rats by a monoclonal antibody that inhibits function of a membrane inhibitor of complement.

Authors:  A Nomura; K Nishikawa; Y Yuzawa; H Okada; N Okada; B P Morgan; S J Piddlesden; M Nadai; T Hasegawa; S Matsuo
Journal:  J Clin Invest       Date:  1995-11       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.